PL3599237T3 - Kompozycja farmaceutyczna inhibitora syntazy glukozyloceramidowej eliglustatu do leczenia choroby Gauchera obejmującego dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 pacjenta - Google Patents

Kompozycja farmaceutyczna inhibitora syntazy glukozyloceramidowej eliglustatu do leczenia choroby Gauchera obejmującego dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 pacjenta

Info

Publication number
PL3599237T3
PL3599237T3 PL19182732T PL19182732T PL3599237T3 PL 3599237 T3 PL3599237 T3 PL 3599237T3 PL 19182732 T PL19182732 T PL 19182732T PL 19182732 T PL19182732 T PL 19182732T PL 3599237 T3 PL3599237 T3 PL 3599237T3
Authority
PL
Poland
Prior art keywords
eliglustat
metabolism
patient
adjustment
treatment
Prior art date
Application number
PL19182732T
Other languages
English (en)
Inventor
Hanlan Liu
Chris Willis
Renu Bhardwaj
Diane P. Copeland
Abizer Harianawala
Jeffrey Skell
John Marshall
Jianmei Kochling
Gerard Palace
Judith Peterschmitt
Craig Siegel
Seng Cheng
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43431870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3599237(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of PL3599237T3 publication Critical patent/PL3599237T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Molecular Biology (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
PL19182732T 2009-11-27 2010-11-24 Kompozycja farmaceutyczna inhibitora syntazy glukozyloceramidowej eliglustatu do leczenia choroby Gauchera obejmującego dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 pacjenta PL3599237T3 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US26474809P 2009-11-27 2009-11-27
EP19182732.8A EP3599237B1 (en) 2009-11-27 2010-11-24 Pharmaceutical composition of the glucosylceramide synthase inhibitor eliglustat for the treatment of gaucher's disease comprising adjusting the individual therapeutical dose to the p450 metabolism of the patient
EP16175117.7A EP3133070B1 (en) 2009-11-27 2010-11-24 Eliglustat (genz 112638) as inhibitor of glucosylceramide synthase for use in a method of treating fabry's or gaucher's disease, the method comprising adjusting the individual therapeutical dose to the p-450 metabolism of the patient
EP16159714.1 2010-11-24
EP14164650.5A EP2796457B1 (en) 2009-11-27 2010-11-24 Genz 112638 for treating Gaucher or Fabry disease in combination therapy
PCT/US2010/057952 WO2011066352A1 (en) 2009-11-27 2010-11-24 An amorphous and a crystalline form of genz 112638 hemitartrat as inhibitor of glucosylceramide synthase
EP10785289.9A EP2504332B2 (en) 2009-11-27 2010-11-24 An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase

Publications (1)

Publication Number Publication Date
PL3599237T3 true PL3599237T3 (pl) 2021-09-27

Family

ID=43431870

Family Applications (4)

Application Number Title Priority Date Filing Date
PL10785289T PL2504332T5 (pl) 2009-11-27 2010-11-24 Amorficzna i krystaliczna postać hemiwinianu genz 112638 jako inhibitor syntazy glukozyloceramidowej
PL14164650T PL2796457T3 (pl) 2009-11-27 2010-11-24 Genz 112638 do leczenia w terapii skojarzonej choroby Gauchera lub choroby Fabry’ego
PL19182732T PL3599237T3 (pl) 2009-11-27 2010-11-24 Kompozycja farmaceutyczna inhibitora syntazy glukozyloceramidowej eliglustatu do leczenia choroby Gauchera obejmującego dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 pacjenta
PL16175117T PL3133070T3 (pl) 2009-11-27 2010-11-24 Eliglustat (Genz 112638) jako inhibitor syntazy glukozyloceramidowej do zastosowania w sposobie leczenia choroby Fabry’ego lub choroby Gauchera, przy czym sposób obejmuje dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 u pacjenta

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL10785289T PL2504332T5 (pl) 2009-11-27 2010-11-24 Amorficzna i krystaliczna postać hemiwinianu genz 112638 jako inhibitor syntazy glukozyloceramidowej
PL14164650T PL2796457T3 (pl) 2009-11-27 2010-11-24 Genz 112638 do leczenia w terapii skojarzonej choroby Gauchera lub choroby Fabry’ego

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL16175117T PL3133070T3 (pl) 2009-11-27 2010-11-24 Eliglustat (Genz 112638) jako inhibitor syntazy glukozyloceramidowej do zastosowania w sposobie leczenia choroby Fabry’ego lub choroby Gauchera, przy czym sposób obejmuje dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 u pacjenta

Country Status (40)

Country Link
US (7) US11458119B2 (pl)
EP (5) EP2796457B1 (pl)
JP (6) JP2013512252A (pl)
KR (6) KR20220162824A (pl)
CN (5) CN112521366A (pl)
AR (3) AR079152A1 (pl)
AU (3) AU2010324810B2 (pl)
BR (1) BR112012012947B8 (pl)
CA (3) CA2781676C (pl)
CL (2) CL2012001348A1 (pl)
CR (1) CR20120277A (pl)
CY (3) CY1115880T1 (pl)
DK (3) DK3133070T3 (pl)
DO (2) DOP2012000141A (pl)
EA (3) EA029990B1 (pl)
EC (2) ECSP12011926A (pl)
ES (4) ES2754398T3 (pl)
GT (1) GT201200161A (pl)
HR (3) HRP20140780T4 (pl)
HU (2) HUE029371T2 (pl)
IL (4) IL310635A (pl)
LT (2) LT2796457T (pl)
MA (1) MA33838B1 (pl)
ME (1) ME02477B (pl)
MX (2) MX381242B (pl)
MY (2) MY160542A (pl)
NI (1) NI201200096A (pl)
NZ (3) NZ715108A (pl)
PE (2) PE20171255A1 (pl)
PH (2) PH12015502514B1 (pl)
PL (4) PL2504332T5 (pl)
PT (4) PT3599237T (pl)
RS (3) RS59543B1 (pl)
SG (2) SG10201407881WA (pl)
SI (3) SI3133070T1 (pl)
SM (1) SMT201600273B (pl)
TN (1) TN2012000237A1 (pl)
TW (3) TWI586663B (pl)
UA (1) UA113491C2 (pl)
WO (1) WO2011066352A1 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
SG10201407881WA (en) 2009-11-27 2015-01-29 Genzyme Corp An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
WO2012177778A1 (en) * 2011-06-20 2012-12-27 Mount Sinai School Of Medicine Anti-tnf- therapy for the mucopolysaccharidoses and other lysosomal disorders
EP3741384A1 (en) 2011-09-07 2020-11-25 Mount Sinai School Of Medicine Ceramidase and cell differentiation
WO2013078413A1 (en) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of lipid storage
CN109529028A (zh) 2012-06-01 2019-03-29 西奈山伊坎医学院 在感染的治疗和预防中的神经酰胺水平
WO2014160390A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them
AU2014321397C1 (en) * 2013-09-20 2019-08-01 Biomarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
US20170129869A1 (en) * 2014-07-03 2017-05-11 Dr. Reddy's Laboratories Limited Amorphous form of eliglustat hemitartarate
ES2716420T3 (es) 2015-04-14 2019-06-12 Sandoz Ag Clorhidrato de eliglustat cristalino
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
JP6895963B2 (ja) 2015-11-18 2021-06-30 ジェンザイム・コーポレーション 多発性嚢胞腎のバイオマーカーおよびその使用
EP3419976B1 (en) 2016-02-25 2021-04-07 Asceneuron SA Acid addition salts of piperazine derivatives
CN107445938B (zh) * 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
CN106349210A (zh) * 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 一种制备酒石酸艾力骨司坦的方法
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
WO2018225085A1 (en) 2017-06-05 2018-12-13 Cipla Limited Stable solid dispersions of eliglustat hemitartrate
AU2018283289B2 (en) * 2017-06-16 2021-03-25 Beta Pharma, Inc. Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
US12472144B2 (en) * 2017-08-08 2025-11-18 Amneal Pharmaceuticals Llc Pharmaceutical composition comprising eliglustat
WO2019030645A1 (en) 2017-08-08 2019-02-14 Kashiv Pharma Llc Pharmaceutical composition comprising eliglustat
CN116139130A (zh) * 2017-12-15 2023-05-23 建新公司 治疗戈谢病的方法
US12064414B2 (en) 2017-12-20 2024-08-20 Aizant Drug Research Solutions Private Limited. Stable amorphous Eliglustat premix and process for the preparation thereof
WO2019211778A2 (en) * 2018-05-02 2019-11-07 Kashiv Biosciences, Llc Pro-drugs of eliglustat
WO2019231725A2 (en) * 2018-05-27 2019-12-05 Bioasis Technolgies Inc. Treatment of gaucher disease
CN110878079A (zh) * 2018-12-31 2020-03-13 北京启慧生物医药有限公司 一种高纯度依利格鲁司他的制备方法
WO2023280381A1 (en) * 2021-07-05 2023-01-12 Asceneuron Sa Medicaments comprising glycosidase inhibitors
CN116120274A (zh) 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 依利格鲁司他可药用盐及其晶型
WO2026006099A1 (en) 2024-06-24 2026-01-02 Genzyme Corporation Eliglustat for the treatment of gaucher disease
EP4725474A1 (en) 2024-10-11 2026-04-15 Genepharm S.A. A solid composition of eliglustat

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3522475A1 (de) 1985-06-22 1987-01-02 Kali Chemie Pharma Gmbh Neue aromatische verbindungen, ihre herstellung und verwendung
US5041441A (en) 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
US5302609A (en) 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
HUT73527A (en) 1993-08-13 1996-08-28 Seikagaku Kogyo Co Ltd Remedy for nervous diseases
US6309823B1 (en) 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
EP1008342A3 (en) 1994-02-02 2004-12-29 The Liposome Company, Inc. Pharmaceutically active compounds and liposomes, and methods of use thereof
WO1995034530A1 (en) 1994-06-10 1995-12-21 Seikagaku Corporation 2-acylaminopropanol compound and medicinal composition
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
US20030073680A1 (en) 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6255336B1 (en) 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US5916911A (en) 1995-09-20 1999-06-29 The Regents Of The University Of Michigan Amino ceramide--like compounds and therapeutic methods of use
JP3993908B2 (ja) 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
EP1098642B1 (en) 1998-07-27 2007-04-04 Johns Hopkins University Diamino-propanol-compounds for treating ischemia
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
EP1384719A1 (en) 1999-07-09 2004-01-28 The Regents of The University of Michigan Inhibitors of the glucosyl ceramide synthase enzyme useful for the treatment of cancers, sphingolipidosis and microbial infections
MXPA02000296A (es) * 1999-07-09 2004-05-21 Univ Michigan Compuestos parecidos a aminoceramida y metodos de uso.
US20040252299A9 (en) 2000-01-07 2004-12-16 Lemmo Anthony V. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
SK9742002A3 (en) * 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
PL358548A1 (pl) 2000-04-24 2004-08-09 Teva Pharmaceutical Industries Ltd. Hemiwinian zolpidemu
US6436987B1 (en) 2000-06-08 2002-08-20 Pfizer Inc. Crystalline forms of (3S-trans)-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid
US20020198240A1 (en) 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
WO2002062777A2 (en) 2001-01-10 2002-08-15 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US7148251B2 (en) 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
MXPA03006294A (es) * 2001-01-18 2003-09-16 Merck Patent Gmbh Proteinas de fusion disfuncionales con actividad glucocerebrosidasa.
PT2266968E (pt) 2001-07-16 2013-02-25 Genzyme Corp Síntese de udp-glucose: inibidores de n-acil esfingosinaglucosiltransferase
EP1281755A3 (en) 2001-07-31 2003-06-18 Pfizer Products Inc. Variants of the human cyp2d6 gene
EP1889839B1 (en) 2001-08-08 2013-11-06 Tobira Therapeutics, Inc. Bicyclic compound, production and use as HIV inhibitors
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
EP1523310A2 (en) 2002-07-09 2005-04-20 The Scripps Research Institute Method to inhibit ischemia and reperfusion injury
US20050032070A1 (en) 2003-08-05 2005-02-10 Sebastian Raimundo Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications
ATE504588T1 (de) * 2004-01-27 2011-04-15 Synthon Bv Stabile salze von olanzapin
ES2375995T3 (es) 2004-09-17 2012-03-08 University Of Massachusetts Composiciones y sus usos para deficiencias de enzima lisosomal.
EP1799865B1 (en) 2004-09-30 2012-06-06 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
CA2584246C (en) 2004-10-13 2011-08-09 Pharmacia & Upjohn Company Llc Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6h)-yl]-n-(2-hydroxyethyl)-4-methylbenzamide
JP2008519840A (ja) * 2004-11-10 2008-06-12 ジェンザイム・コーポレイション 糖尿病の処置方法
WO2007038676A2 (en) * 2005-09-28 2007-04-05 Teva Pharmaceutical Industries Ltd. Polymorphic forms of ladostigil tartrate
WO2007040995A1 (en) * 2005-10-03 2007-04-12 Mallinckrodt Inc. Process for preparing zolpidem hemitartrate and tartrate polymorphs
MX2007016179A (es) 2006-04-17 2008-03-11 Teva Pharma Formas cristalinas de o-desmetilvenlafaxina.
WO2007134086A2 (en) * 2006-05-09 2007-11-22 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
KR101271225B1 (ko) 2006-10-31 2013-06-03 삼성디스플레이 주식회사 발광 다이오드 칩 및 발광 다이오드 광원 모듈의 제조 방법
TWI314226B (en) 2006-12-07 2009-09-01 Ind Tech Res Inst Piezoelectricity-driving optical lens module
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
KR20090104862A (ko) * 2007-01-12 2009-10-06 와이어쓰 정제내 정제 조성물
MX2009010557A (es) 2007-03-30 2009-11-19 Amicus Therapeutics Inc Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas.
WO2008134628A2 (en) * 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2594562B1 (en) * 2007-05-31 2016-07-20 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
DE102007029581B4 (de) 2007-06-26 2020-04-09 GM Global Technology Operations LLC (n. d. Ges. d. Staates Delaware) Kraftfahrzeugdach und Kraftfahrzeugkarosserie
EP2227780A4 (en) 2008-03-19 2011-08-03 Existence Genetics Llc GENETIC ANALYSIS
WO2009117150A2 (en) * 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
PL2604608T3 (pl) 2009-11-27 2016-02-29 Adverio Pharma Gmbh Sposób wytwarzania {4,6-diamino-2-[1-(2-fluorobenzylo)-1H-pirazolo[3,4-b]pirydyn-3-ylo]pirymidyn-5-ylo}metylokarbaminianu metylu
FR2953139B1 (fr) 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
SG10201407881WA (en) 2009-11-27 2015-01-29 Genzyme Corp An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
RU2014101626A (ru) 2011-06-21 2015-07-27 Новартис Аг Полиморфы 2-амид 1-({4-метил-5-[2-(2, 2, 2-трифтор-1, 1-диметил-этил)-пиридин-4-ил]тиазол-2-ил}амида) (s)-пирролидин-1, 2-дикарбоновой кислоты
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
JP6728842B2 (ja) 2016-03-24 2020-07-22 オムロン株式会社 光学計測装置
CN107445938B (zh) 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof

Also Published As

Publication number Publication date
HRP20140780T4 (hr) 2021-08-06
JP2019001809A (ja) 2019-01-10
SMT201600273B (it) 2016-08-31
EP2504332B2 (en) 2021-03-17
AU2016202591A1 (en) 2016-05-19
CR20120277A (es) 2012-09-05
PE20171255A1 (es) 2017-08-28
WO2011066352A1 (en) 2011-06-03
IL260299A (en) 2018-08-30
CN105753846A (zh) 2016-07-13
PH12015502514A1 (en) 2016-08-15
CY1122698T1 (el) 2021-03-12
MA33838B1 (fr) 2012-12-03
HRP20140780T1 (en) 2014-11-07
US20210393590A1 (en) 2021-12-23
SG10201407881WA (en) 2015-01-29
HRP20161038T1 (hr) 2016-10-21
MX2012006083A (es) 2012-06-19
WO2011066352A8 (en) 2011-08-11
AU2010324810A1 (en) 2012-06-07
JP2023116764A (ja) 2023-08-22
JP6370264B2 (ja) 2018-08-08
KR20150125734A (ko) 2015-11-09
CN105777707B (zh) 2020-10-13
US20160120842A1 (en) 2016-05-05
HK1203485A1 (en) 2015-10-30
CN112521367B (zh) 2024-01-02
LT3133070T (lt) 2019-11-11
CA3075788C (en) 2021-12-21
LT2796457T (lt) 2016-09-12
TWI606827B (zh) 2017-12-01
JP7150528B2 (ja) 2022-10-11
NZ600155A (en) 2014-10-31
HRP20191647T1 (hr) 2019-12-13
US11458119B2 (en) 2022-10-04
CA2781676C (en) 2020-05-05
SI2504332T1 (sl) 2014-09-30
IL310635A (en) 2024-04-01
US10888547B2 (en) 2021-01-12
MY160542A (en) 2017-03-15
AR121612A2 (es) 2022-06-22
SG10201800136QA (en) 2018-02-27
TW201737910A (zh) 2017-11-01
KR20200013105A (ko) 2020-02-05
RS54978B1 (sr) 2016-11-30
PT3133070T (pt) 2019-11-11
UA113491C2 (xx) 2017-02-10
DK2504332T4 (da) 2021-06-07
EP3599237A1 (en) 2020-01-29
PL2796457T3 (pl) 2017-04-28
JP2015212291A (ja) 2015-11-26
EP3133070A1 (en) 2017-02-22
US20160166542A1 (en) 2016-06-16
DK3133070T3 (da) 2019-11-11
JP2020189873A (ja) 2020-11-26
EP2796457B1 (en) 2016-05-18
EA201890254A2 (ru) 2018-10-31
GT201200161A (es) 2014-01-27
AU2017265180B2 (en) 2019-08-01
PL2504332T5 (pl) 2021-08-23
PH12015502514B1 (en) 2022-07-29
KR20120115972A (ko) 2012-10-19
CN102712629A (zh) 2012-10-03
US20230172903A1 (en) 2023-06-08
CA2781676A1 (en) 2011-06-03
BR112012012947B1 (pt) 2021-04-06
EP2504332A1 (en) 2012-10-03
DK2796457T3 (en) 2016-08-29
KR102073207B1 (ko) 2020-02-05
MY192644A (en) 2022-08-29
NZ625712A (en) 2016-02-26
PE20121337A1 (es) 2012-10-12
MX381242B (es) 2025-03-12
SI3133070T1 (sl) 2019-11-29
CY1115880T1 (el) 2017-01-25
MX358345B (es) 2018-08-14
ES2493940T3 (es) 2014-09-12
TW201130822A (en) 2011-09-16
RS53503B2 (sr) 2021-07-30
EP2504332B1 (en) 2014-06-04
DOP2012000141A (es) 2012-09-30
ES2493940T5 (es) 2021-11-23
EP3599237B1 (en) 2021-03-24
ES2586947T3 (es) 2016-10-19
TN2012000237A1 (en) 2013-12-12
AR121611A2 (es) 2022-06-22
CN105777707A (zh) 2016-07-20
CN102712629B (zh) 2016-10-12
AU2010324810B2 (en) 2016-05-12
EA201270646A1 (ru) 2013-01-30
CY1117996T1 (el) 2017-05-17
SI2796457T1 (sl) 2016-10-28
PT2796457T (pt) 2016-07-14
ES2754398T3 (es) 2020-04-17
CA3140959A1 (en) 2011-06-03
AR079152A1 (es) 2011-12-28
ECSP18063798A (es) 2020-02-28
EA201890254A3 (ru) 2019-02-28
JP2016138124A (ja) 2016-08-04
CN105753846B (zh) 2019-11-15
AU2017265180A1 (en) 2017-12-14
CN112521367A (zh) 2021-03-19
ME02477B (me) 2017-02-20
HK1172031A1 (en) 2013-04-12
CL2016002589A1 (es) 2017-05-19
EP3133070B1 (en) 2019-08-14
EP3896069A1 (en) 2021-10-20
HUE029371T2 (en) 2017-02-28
US20130137743A1 (en) 2013-05-30
US20260115165A1 (en) 2026-04-30
DK2504332T3 (da) 2014-08-25
KR20220162824A (ko) 2022-12-08
PT2504332E (pt) 2014-09-02
BR112012012947A2 (pt) 2017-03-01
PT3599237T (pt) 2021-04-28
NZ715108A (en) 2017-06-30
RS59543B1 (sr) 2019-12-31
CL2012001348A1 (es) 2012-08-24
HUE045784T2 (hu) 2020-01-28
CN112521366A (zh) 2021-03-19
IL283935A (en) 2021-07-29
PL3133070T3 (pl) 2020-01-31
TWI586663B (zh) 2017-06-11
KR20180049255A (ko) 2018-05-10
SI2504332T2 (sl) 2021-08-31
AU2016202591B2 (en) 2017-11-30
TWI656873B (zh) 2019-04-21
PH12012501048A1 (en) 2013-02-04
EA201592195A1 (ru) 2016-04-29
ECSP12011926A (es) 2012-07-31
ES2875382T3 (es) 2021-11-10
JP2013512252A (ja) 2013-04-11
IL219892A0 (en) 2012-07-31
NI201200096A (es) 2012-10-30
TW201639562A (zh) 2016-11-16
JP6452635B2 (ja) 2019-01-16
RS53503B1 (sr) 2015-02-27
US20210369672A1 (en) 2021-12-02
KR20250005503A (ko) 2025-01-09
EA029990B1 (ru) 2018-06-29
DOP2016000250A (es) 2017-02-15
EP2796457A1 (en) 2014-10-29
US12465586B2 (en) 2025-11-11
PL2504332T3 (pl) 2014-10-31
EA023923B1 (ru) 2016-07-29
CA3075788A1 (en) 2011-06-03
BR112012012947B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
PT3599237T (pt) Composição farmcêutica de eliglustat como inibidor de glicosilceramida-sintase para o tratamento de doença de gaucher compreendendo ajustar a dose terapêutica individual ao metabolismo do p-450 do doente
IL216399A0 (en) Pharmaceutical composition for the treatment of heart diseases
UY32919A (es) Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
ZA201100034B (en) Pharmaceutical compositions for treatment of parkinson's disease
EP2151435A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
IL193727A0 (en) Dosage forms for administering combinations of drugs
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
PT2510916T (pt) Composição farmacêutica antisséptica para a higiene oral e o tratamento de doenças bucais de origem microbiana
UY32487A (es) Composiciones farmacéuticas de liberación inmediata comprendiendo oxicodona y naloxona
IL211293A (en) Combination factors for the preparation of a drug for the treatment of tuberculosis
IL216468B (en) Pharmaceutical compositions deliverable from a metered dose inhaler comprising glycopyrrolate and formoterol and their use in treatment of pulmonary diseases
PL2464342T3 (pl) Formulacje farmaceutyczne do zapobiegania niewłaściwemu użyciu leków medycznych
IL202083A0 (en) Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system
EP2396073A4 (en) IONTOPHORETIC SYSTEM FOR THE TRANSDERMAL ACTIVE SUBSTANCE FOR THERAPEUTIC AND MEDICAL USE
EP2506850A4 (en) METHOD FOR THE ADMINISTRATION OF PIRFENIDON THERAPY
ZA201505849B (en) Composition of novel carbohydrate drug for treatment of human diseases
EP2453886A4 (en) PHARMACEUTICAL PRODUCT FOR ORAL ADMINISTRATION COMPRISING MGBG AND METHODS OF TREATING DISEASE
MY156302A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES
IL202111A0 (en) Formulations for the oral administration of therapeutic agents and related methods
EP2306824A4 (en) IONTOPHORETIC DELIVERY OF CURCUMINE AND CURCUMINANALOGUE FOR THE TREATMENT OF MORBUS ALZHEIMER
WO2009099553A3 (en) Use of kinase inhibitor in treatment of atherosclerosis
EP2168586A4 (en) ACTIVE AGENT, REMEDY, PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF PATIENTS WITH DENTAL SYNDROME
DK2244703T3 (da) Lægemiddel og fremstillingen og anvendelse deraf i behandlingen af smertefulde neuropatier
EP2213303A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CATARACT
ZA201003291B (en) Device for delivering a plurality of medical treatment liquids to a human or animal patient